Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells
Gene-modified B cells expressing immunoglobulin G (IgG) fusion proteins have been shown to induce tolerance in several autoimmune and other disease models. However, lack of a vector suitable for gene transfer to human B cells has been an obstacle for translation of this approach. To overcome this hu...
Main Authors: | Xiaomei Wang, Roland W. Herzog, Barry J. Byrne, Sandeep R.P. Kumar, Qi Zhou, Christian J. Buchholz, Moanaro Biswas |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-06-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050117300505 |
Similar Items
-
The molecular basis of hemophilia B : identification of the defect in factor IXVancouver
by: Geddes, Valerie Anne
Published: (2010) -
Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
by: Alexandra Sherman, et al.
Published: (2017-11-01) -
Christmas Disease (Hemophilia B) A Case Report
by: Md Rafiqul Alam, et al.
Published: (2010-04-01) -
Reprogrammed CD4+ T Cells That Express FoxP3+ Control Inhibitory Antibody Formation in Hemophilia A Mice
by: Roland W. Herzog, et al.
Published: (2019-02-01) -
Development of approaches for immunotherapy by chimeric antigen receptor modified hematopoietic stem cell transfer
by: Badowski, Michael Steven
Published: (2009)